Cargando…

In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019

PURPOSE: Lefamulin is a novel antibiotic approved by the U.S. Food and Drug Administration in 2019 for the treatment of community-acquired bacterial pneumonia (CABP). In this study we evaluated the in vitro antimicrobial activity of lefamulin in order to better understand its antibiogram. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shi, Zheng, Yonggui, Guo, Yan, Yin, Dandan, Zhu, Demei, Hu, Fupin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525147/ https://www.ncbi.nlm.nih.gov/pubmed/33042095 http://dx.doi.org/10.3389/fmicb.2020.578824

Ejemplares similares

In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
por: Wu, Shi, et al.
Publicado: (2022)

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)
por: Dandan, Yin, et al.
Publicado: (2022)

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
por: Rodvold, Keith A
Publicado: (2019)

1320. In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
por: Sader, Helio S, et al.
Publicado: (2021)

In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019
por: Guo, Yan, et al.
Publicado: (2022)

Epidemiological and genetic characteristics of swine pseudorabies virus in mainland China between 2012 and 2017
por: Sun, Ying, et al.
Publicado: (2018)

Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China
por: Han, Renru, et al.
Publicado: (2020)

In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
por: Paukner, Susanne, et al.
Publicado: (2017)

Evaluation of the Immunochromatographic NG-Test Carba 5, RESIST-5 O.O.K.N.V., and IMP K-SeT for Rapid Detection of KPC-, NDM-, IMP-, VIM-type, and OXA-48-like Carbapenemase Among Enterobacterales
por: Han, Renru, et al.
Publicado: (2021)

Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019
por: Ding, Li, et al.
Publicado: (2022)

Epidemiological features and spatial-temporal clustering of visceral leishmaniasis in mainland China from 2019 to 2021
por: Li, Yuanyuan, et al.
Publicado: (2022)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Clinical Utility of Lefamulin: If Not Now, When?
por: Mercuro, Nicholas J., et al.
Publicado: (2020)

Genetic characterization and molecular epidemiology of Coxsackievirus A12 from mainland China during 2010–2019
por: Guo, Qin, et al.
Publicado: (2022)

Prevalence of Common Respiratory Viral Infections and Identification of Adenovirus in Hospitalized Adults in Harbin, China 2014 to 2017
por: Wang, Yingchen, et al.
Publicado: (2018)

Lefamulin. Comment on: “Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270”
por: Koulenti, Despoina, et al.
Publicado: (2019)

In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China
por: Han, Renru, et al.
Publicado: (2022)

703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)
por: Sader, Helio S, et al.
Publicado: (2019)

Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis
por: Spiller-Boulter, Oliver, et al.
Publicado: (2021)

1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States
por: Paukner, Susanne, et al.
Publicado: (2018)

Klebsiella pneumoniae: Development of Carbapenem Resistance due to Acquisition of bla(NDM-1) During Antimicrobial Therapy in Twin Infants with Pneumonia
por: Zhu, Junying, et al.
Publicado: (2015)

Emergence of ST15 Klebsiella pneumoniae Clinical Isolates Producing Plasmids-Mediated RmtF and OXA-232 in China
por: Shi, Qingyu, et al.
Publicado: (2020)

Genetic Diversity, Evolutionary Dynamics, and Pathogenicity of Ferret Badger Rabies Virus Variants in Mainland China, 2008–2018
por: Miao, Faming, et al.
Publicado: (2022)

Pathogenic Characterization of European Genotype Porcine Reproductive and Respiratory Syndrome Virus Recently Isolated in Mainland China
por: Ming, Sun, et al.
Publicado: (2017)

Genetic characterization and pathogenicity of H7N9 highly pathogenic avian influenza viruses isolated from South China in 2017
por: Zhao, Bingbing, et al.
Publicado: (2023)

Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials
por: Paukner, Susanne, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin
por: Eraikhuemen, Nathaniel, et al.
Publicado: (2021)

Molecular Characterization and Antibiotic Resistant Profiles of Campylobacter Species Isolated From Poultry and Diarrheal Patients in Southeastern China 2017–2019
por: Zhang, Leyi, et al.
Publicado: (2020)

In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
por: Paukner, Susanne, et al.
Publicado: (2017)

697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018
por: Yang, Yang, et al.
Publicado: (2019)

Tissue Distribution of [(14)C]-Lefamulin into the Urogenital Tract in Rats
por: Wicha, Wolfgang W., et al.
Publicado: (2022)

Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates
por: Han, Renru, et al.
Publicado: (2022)

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
por: Alexander, Elizabeth, et al.
Publicado: (2018)

The Emerging Role of Rhinoviruses in Lower Respiratory Tract Infections in Children – Clinical and Molecular Epidemiological Study From Croatia, 2017–2019
por: Ljubin-Sternak, Sunčanica, et al.
Publicado: (2019)

Occurrence of NDM-1, VIM-1, and OXA-10 Co-Producing Providencia rettgeri Clinical Isolate in China
por: Shen, Siquan, et al.
Publicado: (2022)

Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia
por: Adhikary, Shubham, et al.
Publicado: (2022)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pfhselpv8d5nvssmi2oqgc328b